Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: Tomato who wrote (463)	1/27/2001 11:23:43 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 1833

recap.com Message 13711653 osip.com ............... GPCR DIRECTED OSI OWNED: (ADENOSINE RECEPTORS): - 1 target in IND track - Heart Disease - 3 targets in Lead Optimization - Asthma/Inflammation - Glaucoma OSI/SOLVAY FUNDED COLLABORATION WITH MILESTONES & ROYALTIES: - Parkinson's Disease - 1 target in IND track (licensed to Solvay with milestones & royalties) - multiple targets in Lead Seeking sec.gov more GPCR -- Directed Drug Discovery In August, 1999, OSI purchased certain assets of Cadus Pharmaceuticals Corporation. In this acquisition, OSI acquired Cadus' drug discovery programs focused on G-protein coupled receptors or GPCRs. These receptors are one of the most important families of targets for drug discovery in the pharmaceutical industry. Approximately, forty percent of the currently marketed pharmaceutical products target GPCRs. The acquired programs include Cadus' discovery program in adenosine receptors, an important family of GPCR's. These programs will form the core of OSI-owned and funded candidate development programs in the coming year.

To: Tomato who wrote (463)	1/27/2001 11:28:45 PM
From: scaram(o)uche	Respond to of 1833

There are only a few hundred messages in the thread, and there's a lot of decent content. If you've already read it, you might consider making copies or notes next time? Thanks. >> you felt that KDUS might be earning $4 or so per share by 2004 or 2005 << I believe that I said that I estimate 2005 royalties at $16 million. I had made an earlier estimate ($24 million??), but I lowered it. That's a big difference, and I'd appreciate your not attributing crap like that to me. Thanks again. Unless something has changed (and I'm going to be very ticked if it has), royalties derive from the first of two potential products, not both. The potential products are the OSIP-proprietary project (asthma) or the OSIP-Solvay project (CHF), and I'm using 4%. That estimate may be high. If it's 2%, then my estimate would be $8 million, etc. Potential milestones (small, described in the thread?) could (and I believe should) derive from a combination of the projects.